Capital Granite, L.P.Saints... Net Worth

The estimated Net Worth of Capital Granite, L.P.Saints... is at least $23.3 Million dollars as of 11 October 2013. Capital Saints owns over 32,301 units of Enanta Pharmaceuticals Inc stock worth over $17,165,524 and over the last 12 years Capital sold ENTA stock worth over $6,128,906.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Saints ENTA stock SEC Form 4 insiders trading

Capital has made over 4 trades of the Enanta Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital sold 32,301 units of ENTA stock worth $640,852 on 11 October 2013.

The largest trade Capital's ever made was selling 200,000 units of Enanta Pharmaceuticals Inc stock on 30 September 2013 worth over $4,702,000. On average, Capital trades about 83,746 units every 50 days since 2013. As of 11 October 2013 Capital still owns at least 1,425,708 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Capital Saints stock trades at the bottom of the page.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.

What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Complete history of Capital Saints stock trades at Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jay Luly,
  President, Chief Executive Officer, Director
• Yat Sun Or,
  Senior Vice President - Research & Development, Chief Scientific Officer
• Nathalie Adda,
  Senior Vice President and Chief Medical Officer
• Paul Mellett,
  Chief Financial Officer, Senior Vice President - Finance & Administration
• Nathaniel Gardiner,
  Senior Vice President, General Counsel
• Dr. Jay R. Luly,
  Pres, CEO & Director
• Dr. Yat Sun Or,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Nathalie Adda,
  Sr. VP & Chief Medical Officer
• Nathaniel S. Gardiner J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Paul J. Mellett Jr.,
  Sr. VP of Fin. & Admin. and CFO
• Bruce Carter,
  Independent Non-Executive Chairman of the Board
• Terry Vance,
  Independent Director
• George Golumbeski,
  Independent Director
• Lesley Russell,
  Independent Director
• Kristine Peterson,
  Independent Director
• Mark Foletta,
  Independent Director
• Carol Miceli,
  Director, Investor Relations
• Brendan Luu,
  Sr. VP of Bus. Devel.
• Tara Lynn Kieffer Ph.D.,
  Sr. VP of New Product Strategy & Devel.
• Jennifer Viera,
  Sr. Director of Investor Relations & Corp. Communications
• Ernst Guenter Afting,
  Director
• Tim Ocain,
  Senior Vice President
• Stephen Jr. Buckley,
  Director
• V Life Science Ventures Gmb...,
  
• V Life Science Ventures Gmb...,
  
• Helmut Schuhsler,
  Director
• David Poorvin,
  Director
• Capital Granite, L.P.M Rna ...,
  
• Marc E. Goldberg,
  Director
• Gregory L. Verdine,
  Director
• & Co Ltd Shionogi,
  10% owner
• Yujiro S Hata,
  Director
• Brendan Luu,
  Chief Business Officer
• Scott T. Rottinghaus,
  Chief Medical Officer
• Tara Lynn Kieffer,
  Chief Product Strategy Officer
• Matthew Paul Kowalsky,
  Chief Legal Officer